Off-Label Use of Upadacitinib for Treatment of Lichen Planus: A Narrative Review
Keywords:
upadacitinib, janus kinase, JAK inhibitor, lichen planus, lichen planopilarisAbstract
Introduction: Lichen planus (LP) is a chronic inflammatory disorder that primarily affects middle-aged adults and can involve the skin (cutaneous LP), mucous membranes (oral, esophageal, ocular, or vulvar LP), hair (lichen planopilaris, LPP), and nails. The exact cause of LP is not known, but the pathogenesis is thought to be multifactorial and involves T-cell mediated attack of skin and mucous membranes.
Objectives: The purpose of this review was to summarize the available reports regarding treatment of LP with the selective and reversible Janus kinase (JAK) 1 inhibitor upadacitinib.
Methods: PubMed and Google Scholar databases were queried using LP and upadacitinib terms with Boolean operators and assessed using the Oxford evidence criteria.
Results: Sixteen reports were included, comprising a 27 total of patients (19 females and eight males). Most cases were cutaneous LP (N=14, 51.8%) and LPP (N=6, 22.2%). Prior treatments included topical corticosteroids (N=21, 77.8%) and disease-modifying antirheumatic drugs (DMARDs) (N=14, 51.9%). The most common upadacitinib dosages were 15 mg once daily (N=19, 70.4%) and 30 mg once daily (N=5, 18.5%). Most patients achieved remission (N=21, 77.8%) after a median one month which lasted a median three months after treatment cessation or five months in patients who continued to receive treatment. Upadacitinib therapy had minimal, self-limited side effects (N=4, 14.8%).
Conclusions: Upadacitinib demonstrates potential as a tolerable and effective off-label treatment for LP. Larger studies are warranted to better define the safety and efficacy of upadacitinib in treating LP.
References
Boch K, Langan EA, Kridin K, Zillikens D, Ludwig RJ, Bieber K. Lichen Planus. Front Med. 2021;8. DOI:10.3389/fmed.2021.737813.
Gorouhi F, Davari P, Fazel N. Cutaneous and Mucosal. Lichen Planus: A Comprehensive Review of Clinical. Subtypes, Risk Factors, Diagnosis, and Prognosis. ScientificWorldJournal. 2014;2014:742826. DOI:10.1155/2014/742826.
Pilli M, Penna A, Zerbini A, et al. Oral. lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology. 2002;36(6):1446. DOI:10.1002/hep.1840360622.
de Vries HJC, Teunissen MBM, Zorgdrager F, Picavet D, Cornelissen M. Lichen planus remission is associated with a decrease of human herpes virus type 7 protein expression in plasmacytoid dendritic cells. Arch Dermatol Res. 2007;299(4):213-219. DOI:10.1007/s00403-007-0750-0.
Wang Y, Shang S, Sun Q, et al. Increased infiltration of CD11 c+/CD123+ dendritic cell subsets and upregulation of TLR/IFN-α signaling participate in pathogenesis of oral lichen planus. Oral Surg Oral. Med Oral Pathol Oral Radiol. 2018;125(5):459-467.e2. DOI:10.1016/j.oooo.2017.12.003.
González Moles M, Esteban F, Ruiz-Ávila I, et al. A role for the substance P/NK-1 receptor complex in cell proliferation and apoptosis in oral lichen planus. Oral Diseases. 2009;15(2):162-169. DOI:10.1111/j.1601-0825.2008.01504.x.
Doche I, Wilcox GL, Ericson M, et al. Evidence for neurogenic inflammation in lichen planopilaris and frontal. fibrosing alopecia pathogenic mechanism. Experimental. Dermatology. 2020;29(3):282-285. DOI:10.1111/exd.13835.
Cooper SM, Dean D, Allen J, Kirtschig G, Wojnarowska F. Erosive lichen planus of the vulva: weak circulating basement membrane zone antibodies are present. Clin Exp Dermatol. 2005;30(5):551-556. DOI:10.1111/j.1365-2230.2005.01866.x.
Howard A, Dean D, Cooper S, Kirtshig G, Wojnarowska F. Circulating basement membrane zone antibodies are found in lichen sclerosus of the vulva. Australas J Dermatol. 2004;45(1):12-15. DOI:10.1111/j.1440-0960.2004.00026.x.
Cooper SM, Ali I, Bal.do M, Wojnarowska F. The Association of Lichen Sclerosus and Erosive Lichen Planus of the Vulva With Autoimmune Disease: A Case-Control Study. Archives of Dermatology. 2008;144(11):1432-1435. DOI:10.1001/archderm.144.11.1432.
Di Lernia V. Targeting the IFN-γ/CXCL10 pathway in lichen planus. Med Hypotheses. 2016;92:60-61. DOI:10.1016/j.mehy.2016.04.042.
Yu F, Wu W, Chen S, Yang B. Successful treatment of childhood lichen planus with upadacitinib. Postepy Dermatol Alergol. 2024;41(1):139-141. DOI:10.5114/ada.2023.135616.
McNamara ME, Tjahjono L. Successful treatment of recalcitrant cutaneous lichen planus and unusual variants with upadacitinib: A case series and a literature review of systemic Janus kinase inhibitors use in cutaneous lichen planus and lichen planopilaris. JAAD Case Reports. 2025;59:147-154. DOI:10.1016/j.jdcr.2025.01.014
Politou M, Almpanis Z, Fekkas N. 52231 Upadacitinib for the treatment of recalcitrant lichen planopilaris: First case reported. Journal of the American Academy of Dermatology. 2024;91(3):AB95. DOI:10.1016/j.jaad.2024.07.384.
Lasheras-Pérez MA, Palacios-Diaz RD, Pujol-Marco C, Escutia-Muñoz B, Botella-Estrada R. Recalcitrant lichen planopilaris treated with upadacitinib: a case series. Int J Dermatol. 2024;63(12):1802-1804. DOI:10.1111/ijd.17339.
Xia M, Zhang J, Tian X, Chen Z, Liang J, Liu Y. Successful Treatment of Ustekinumab-Associated Lichenoid Drug Eruption with Upadacitinib: A Case Report. Clin Cosmet Investig Dermatol. 2025;18:801-804. DOI:10.2147/CCID.S513281.
Balestri R, Bortolotti R, Rech G, Girardelli CR, Zorzi MG, Magnano M. Treatment of Oral Erosive Lichen Planus With Upadacitinib. JAMA Dermatol. 2022;158(4):457-458. DOI:10.1001/jamadermatol.2022.0147
Gueissaz L, Wolf R, Schlapbach C. Rapid and Sustained Improvement of Lichen Planus Pemphigoides With the JAK1 Inhibitor Upadacitinib. JEADV Clinical Practice. Published online December 18, 2024:jvc2.603. DOI:10.1002/jvc2.603.
Ying Y, Jia-Min H, Zhao-Jun S. Treating Inverse Lichen Planus With Upadacitinib: A Case Study. Australas J Dermatol. 2025;66(3):e182-e184. DOI:10.1111/ajd.14459.
Kooybaran NR, Petzold G, Ströbel P, Schön MP, Mössner R. Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib. J Dtsch Dermatol Ges. 2021;19(12):1778-1780. DOI:10.1111/ddg.14612.
Schundler SF, Noot CH, Frost Z, Clarke J, Hopkins ZH. Treatment of recalcitrant hypertrophic lichen planus with upadacitinib. JAAD Case Rep. 2025;59:78-80. DOI:10.1016/j.jdcr.2025.02.029.
Sheehan CA, Brownstone ND, Lee JB, Hsu S. Successful Use of Upadacitinib for Recalcitrant Oral Erosive Lichen Planus. JAAD Case Reports. Published online March 2025:S2352512625001158. DOI:10.1016/j.jdcr.2025.02.042.
Becker EC, Mavilia-Scranton M, Finch J, Yu M, Rezaizadeh H. Use of Upadacitinib in Refractory Esophageal Lichen Planus: Endoscopic Improvement in “Planus” Sight. ACG Case Rep J. 2023;10(11):e01200. DOI:10.14309/crj.0000000000001200.
Böll SL, Zahn CA, Schlapbach C. Rapid and sustained improvement of cutaneous lichen planus with oral JAK1 inhibitors. J Eur Acad Dermatol Venereol. 2024;38(1):e82-e85. DOI:10.1111/jdv.19440.
Zundell MP, Kaminetsky J, Lebwohl M, Gottlieb AB. Successful Treatment of Lichen Planus With Oral Upadacitinib. J Drugs Dermatol. 2023;22(10):1058-1060. DOI:10.36849/JDD.7272.
Landells FM, Goudie S, McGrath J, Tibbo J, Landells ID. Successful treatment of erosive lichen planus with Upadacitinib complicated by oral squamous cell carcinoma. SAGE Open Med Case Rep. 2023;11:2050313X231213144. DOI:10.1177/2050313X231213144.
Rosenbaum C, Tan VT, Grekin JA, Fulton E, Treyger G. Unilateral blaschkoid lichen planus successfully treated with upadacitinib. JAAD Case Rep. 2024;45:35-37. DOI:10.1016/j.jdcr.2024.01.007.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mark Gregory, Negar Esfandiari, Steven Daveluy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
